Meanwhile, Samchundang Pharm shares dropped nearly 9% following news that the Financial Supervisory Service (FSS) is investigating the company for potential violations of its disclosure obligations.
BL Pharmtech stock trend. (KG Zeroin)
◇BL Pharmtech hits upper limit on tangible results
According to KG Zeroin MP Doctor, BL Pharmtech's stock showed strength from the opening bell. It reached the daily limit in the afternoon, closing at 3,535 won, up 815 won from the previous day's close. The stock has been on an upward trend for about 10 days, surging approximately 118% from its June 22 close of 1,632 won.
The recent surge is attributed to global interest and expectations surrounding its molecular glue platform technology and its applied pipeline, "ML301."
BL Pharmtech announced that it had established cooperation bases with global pharmaceutical companies and investment firms at the recent BIO International Convention 2026 (BIO USA). It also signed non-disclosure agreements (NDAs) and agreed to share follow-up data with multiple global companies.
Specifically, the chief scientific officer and head of business development at a global pharmaceutical company currently supporting BL Pharmtech's technology development positively evaluated the potential for out-licensing the preclinical and early clinical pipeline. The two companies plan to discuss development progress and follow-up cooperation plans at the U.S. headquarters in October.
Furthermore, the head of business development at a global biotech specializing in anticancer drugs showed high interest in BL Pharmtech's molecular glue-based anticancer project. They agreed to share confidential data after signing an NDA and will conduct an in-depth review for potential technology adoption.
A French pharmaceutical company noted the potential of developing BL Pharmtech's anticancer candidate as a small-molecule treatment for brain tumors. The two sides agreed to share development status and research data after signing an NDA, with a technology export in mind.
The company also achieved results in strategic consulting and investment networking for its global market entry. A U.S. firm specializing in drug development incubation and business development consulting decided to actively support maximizing BL Pharmtech's technology asset value and finding global partners based on its infrastructure and asset-matching services.
In addition, a major U.K. investment firm and global biotech specializing in anticancer drugs expressed its intention to support the translational research stage prior to clinical entry using its clinical network in the U.K. After signing an NDA, the two companies agreed to share detailed data and discuss specific cooperation models.
"This BIO USA was a meaningful event that confirmed the innovation and global competitiveness of our molecular glue-based anticancer pipeline and early development assets," a BL Pharmtech official said. "We will do our best to create tangible business results, such as joint research and early technology exports, by quickly signing NDAs and sharing research data with the global companies we met."
◇Raphas draws attention with Hosokawa Micron partnership
Raphas shares closed at 9,080 won, up 9.27% from the previous day. The rise is analyzed to be a result of the partnership with Hosokawa Micron announced the previous day.
On July 1, Raphas announced it would target the cosmetics and pharmaceutical markets based on a next-generation drug delivery system (DDS) alongside Hosokawa Micron, a leading global advanced materials company based in Japan.
Raphas signed a three-party strategic alliance agreement with Hosokawa Micron and its local subsidiary, Raphas Japan, to commercialize the fusion of "advanced nanoparticle technology" and "microneedle manufacturing technology."
Specifically, Raphas plans to equip its microneedle patch technology with Hosokawa Micron's proprietary "PLGA (poly lactic-co-glycolic acid) nanocomposite encapsulation technology." The two companies successfully completed prototype verification earlier this year and have now entered the full-scale stage for commercialization.
"Because Hosokawa Micron is relatively unknown in South Korea, the market response seemed a bit delayed as analysis of the company was taking place," a Raphas official said. "The fact that a global materials company like Hosokawa Micron selected Raphas as its exclusive manufacturing and commercialization partner is a result of our microneedle technology's platform value and production capacity being officially recognized in the market."
◇Samchundang Pharm drops 9% on news of FSS probe
Samchundang Pharm shares closed at 204,000 won, down 8.72% from the previous day. The drop is interpreted as being influenced by news that the FSS has launched a formal investigation into the company.
A news outlet reported the previous day that following the Korea Exchange's designation of Samchundang Pharm as an unfaithful disclosure corporation and the imposition of penalty points, the FSS is intensively looking into whether the company violated disclosure obligations, such as stating false facts in its regulatory filings.
In April, the Kosdaq Market Division of the Korea Exchange designated Samchundang Pharm as an unfaithful disclosure corporation and imposed five penalty points for "failure to fulfill fair disclosure regarding forecasts or predictions of business performance."
In response, Samchundang Pharm stated on its website that the "designation as an unfaithful disclosure corporation is a procedural issue with fair disclosure" and is unrelated to false disclosures.
According to Samchundang Pharm, the reason for the designation was the penalty points incurred from distributing a press release about the performance in the Canadian market of its Eylea biosimilar, "SCD411," before going through formal disclosure procedures. This was a measure taken for insufficiently fulfilling the fair disclosure procedure obligations under the Capital Markets Act, not a false disclosure, the company argued.
Regarding contracts in the U.S. and European markets, the company drew a line, stating, "It is a completely separate matter from the large-scale overseas contracts mentioned in the report."
"The core business and global operations currently underway are proceeding normally without any setbacks," Samchundang Pharm said. "We will do our best to restore market trust and enhance shareholder value based on transparent management and sincere communication."
